ArriVent BioPharma aims to raise $75 million in a public stock sale, using the proceeds to advance its lung cancer drug and other pipeline programs.

Proposed cuts will have “a catastrophic effect on the advancement of biomedical and biotechnology capabilities in the United States,” more than 100 leaders of biomedical/health sciences ...

BioNTech SE, in collaboration with Genentech, Inc., is conducting a Phase II study titled ‘A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX ...

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB (TM), its New Sublingual Pre-Workout Supplement Written by aspire biopharma holdings inc.

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB (TM), its New Sublingual Pre-Workout Supplement Written by aspire biopharma holdings inc.

Immix Biopharma does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as ...

BioNTech ADR BNTX saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 73.

Ultragenyx and Mereo BioPharma are collaborating on the development of setrusumab globally based on the collaboration and license agreement between the parties.

--COSCIENS Biopharma Inc., a life sciences company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today announced the voting ...

The Food and Drug Administration (FDA) has expanded its warnings on Pfizer and Moderna COVID-19 vaccines about the risks of two heart conditions. These manufacturers, the two main COVID-19 vaccine ...

BioNTech and OncoC4 reported Phase 1/2 data in non-small cell lung cancer for an immunotherapy called gotistobart. Earlier this year, the German company inked a deal to share in the development of ...